|
|
Blood, 15 November 2004, Vol. 104, No. 10, pp. 3021-3027.
Prepublished online as a Blood First Edition Paper on July 29, 2004; DOI 10.1182/blood-2004-02-0701.
 Previous Article | Table of Contents | Next Article 
CHEMOKINES
Monocyte-like and mature macrophages produce CXCL13 (B cell–attracting chemokine 1) in inflammatory lesions with lymphoid neogenesis
Hege S. Carlsen,
Espen S. Baekkevold,
H. Craig Morton,
Guttorm Haraldsen, and
Per Brandtzaeg
From the Laboratory for Immunohistochemistry and Immunopathology (LIIPAT), Institute of Pathology, and the Department of Surgery, Rikshospitalet University Hospital, Oslo, Norway.
The homeostatic chemokine CXCL13 (also called B cell-attracting chemokine 1 [BCA-1] or B-lymphocyte chemoattractant [BLC]) is constitutively expressed in secondary lymphoid tissue and initiates lymphoid neogenesis when expressed aberrantly in mice. CXCL13 has also been detected in chronic inflammation associated with human lymphoid neogenesis, suggesting a pathogenic role. Follicular dendritic cells (FDCs) are generally considered to be the major source of CXCL13 both in normal and aberrant lymphoid tissue. We show here, instead, that most CXCL13-expressing cells in rheumatoid arthritis and ulcerative colitis are of monocyte/macrophage lineage. They are located in irregular lymphoid aggregates within an FDC network, but also within and near smaller collections of B cells in diseased tissue where no FDCs are detected. Some of these CXCL13-expressing cells are CD14+, suggesting derivation from recently extravasated monocytes. Interestingly, monocytes from healthy donors stimulated in vitro with lipopolysaccharide secrete CXCL13. This induced production is enhanced after in vitro maturation of the monocytes toward macrophages but markedly decreased after maturation toward dendritic cells. Together, our findings strongly suggest that newly recruited monocytes/macrophages play a role for lymphoid neogenesis in human inflammatory diseases. Circulating monocytes are therefore potential candidates for future targeted therapy of chronic inflammation.
 CiteULike  Connotea  Del.icio.us  Digg  Reddit  Technorati What's this?
This article has been cited by other articles:
|
|
|
|
 
A. Burkle, M. Niedermeier, A. Schmitt-Graff, W. G. Wierda, M. J. Keating, and J. A. Burger
Overexpression of the CXCR5 chemokine receptor, and its ligand, CXCL13 in B-cell chronic lymphocytic leukemia
Blood,
November 1, 2007;
110(9):
3316 - 3325.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
L. Lasagni, R. Grepin, B. Mazzinghi, E. Lazzeri, C. Meini, C. Sagrinati, F. Liotta, F. Frosali, E. Ronconi, N. Alain-Courtois, et al.
PF-4/CXCL4 and CXCL4L1 exhibit distinct subcellular localization and a differentially regulated mechanism of secretion
Blood,
May 15, 2007;
109(10):
4127 - 4134.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
O. M. Steinmetz, R. A. K. Stahl, and U. Panzer
Formation of lymphoid-like tissue in the kidney--is there a role for chemokines?
Nephrol. Dial. Transplant.,
February 1, 2007;
22(2):
350 - 352.
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. Meraouna, G. Cizeron-Clairac, R. L. Panse, J. Bismuth, F. Truffault, C. Tallaksen, and S. Berrih-Aknin
The chemokine CXCL13 is a key molecule in autoimmune myasthenia gravis
Blood,
July 15, 2006;
108(2):
432 - 440.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
L. V. Bagaeva, P. Rao, J. M. Powers, and B. M. Segal
CXC chemokine ligand 13 plays a role in experimental autoimmune encephalomyelitis.
J. Immunol.,
June 15, 2006;
176(12):
7676 - 7685.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. O. Orlova, K. B. Majorov, I. V. Lyadova, E. B. Eruslanov, C. E. M'lan, C. M. T. Greenwood, E. Schurr, and A. S. Apt
Constitutive differences in gene expression profiles parallel genetic patterns of susceptibility to tuberculosis in mice.
Infect. Immun.,
June 1, 2006;
74(6):
3668 - 3672.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
Q. Pan, V. Kravchenko, A. Katz, S. Huang, M. Ii, J. C. Mathison, K. Kobayashi, R. A. Flavell, R. D. Schreiber, D. Goeddel, et al.
NF-{kappa}B-Inducing Kinase Regulates Selected Gene Expression in the Nod2 Signaling Pathway
Infect. Immun.,
April 1, 2006;
74(4):
2121 - 2127.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
W. Vermi, F. Facchetti, E. Riboldi, H. Heine, S. Scutera, S. Stornello, D. Ravarino, P. Cappello, M. Giovarelli, R. Badolato, et al.
Role of dendritic cell-derived CXCL13 in the pathogenesis of Bartonella henselae B-rich granuloma
Blood,
January 15, 2006;
107(2):
454 - 462.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. Krumbholz, D. Theil, S. Cepok, B. Hemmer, P. Kivisakk, R. M. Ransohoff, M. Hofbauer, C. Farina, T. Derfuss, C. Hartle, et al.
Chemokines in multiple sclerosis: CXCL12 and CXCL13 up-regulation is differentially linked to CNS immune cell recruitment
Brain,
January 1, 2006;
129(1):
200 - 211.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
H. S. Carlsen, G. Haraldsen, P. Brandtzaeg, and E. S. Baekkevold
Disparate lymphoid chemokine expression in mice and men: no evidence of CCL21 synthesis by human high endothelial venules
Blood,
July 15, 2005;
106(2):
444 - 446.
[Abstract]
[Full Text]
[PDF]
|
|
|
| |
